FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2223-2224 May 24, 2007 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bladé, J. PubMed Citation

To the Editor: In the article concerning monoclonal gammopathy of undetermined significance (MGUS) (Dec. 28 issue),¹ Bladé disregards a complication that is especially important in clinical practice. Indeed, the problem of skeletal involvement in this disease should not be viewed only as a way to rule out lytic lesions but should be placed in a more comprehensive context. We² and others³ have reported an increased rate of vertebral fractures among patients with MGUS. This increase is probably secondary to an altered balance between the receptor activator of nuclear factor–B ligand (RANKL) and osteoprotegerin.^2,4 This is important for two reasons. . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.